AMCP 2026
April 13 - 16 | Nashville, TN
April 2026
Carelon Research will be joining more than 4,000 managed care decision makers at AMCP 2026 in Nashville, TN. Connect with our experts and see our latest research.
Carelon Research presentations
Carelon Research authors are indicated in bold.
*Associate at time of study
|
Presentation |
Session |
Title |
Authors |
Affiliations |
|---|---|---|---|---|
|
Tuesday, April 14, 2026 |
Spotlight Session |
Real-World Identification of Obesity: Development and Internal Validation of a Claims-Based Machine Learning Algorithm |
Head MA [1], Chhibber A [2], Venkataraman M [1], Kuti E [2], Teng CC [1], Lartey L [2], Donato BM [2], Tan H [1] |
[1] Carelon Research; |
|
Tuesday, April 14, 2026 |
Spotlight Session |
Understanding recent self-reported biosimilar use among individuals with IBD |
Daugherty, S [1] |
[1] Carelon Research |
|
Tuesday, April 14, 2026 Wednesday, April 15, 2026 |
Poster Session |
[139] Cost per responder analysis of tirzepatide versus semaglutide in GLP-1 RA-naive patients with T2D |
Terrell K [1], Vallarino C [2], Maldonado J [3], Grabner M [4], Teng C [4], Hoog M [2], Richard E [4] |
[1] Eli Lilly and Company, Indianapolis; |
|
Tuesday, April 14, 2026 Wednesday, April 15, 2026 |
Poster Session |
[140] Cost per responder analysis of tirzepatide versus semaglutide in GLP-1 RA-experienced patients with T2D |
Terrell K [1], Vallarino C [2], Maldonado J [3], Grabner M [4], Teng C [4], Hoog M [2], Richard E [4] |
[1] Eli Lilly and Company, Indianapolis; |
|
Tuesday, April 14, 2026 4:30 PM – 5:30 PM CT Wednesday, April 15, 2026 12:00 PM – 1:00 PM CT |
Poster Session |
[142] Individuals with obesity or overweight who switched to tirzepatide from another GLP-1 RA obesity management medication demonstrated clinically meaningful weight reduction after persistent tirzepatide use: Results from 2 real-world studies |
Chinthammit C [1], Gibble T [1], Mojdami D [1], Crocker K [2], Vallarino C [1], Huang A [3], Dehghan M [1], Bays H [4], Lubelczyk E [1] |
[1] Eli Lily and Company; |
|
Tuesday, April 14, 2026 4:30 PM – 5:30 PM CT
12:00 PM – 1:00 PM CT |
Poster Session |
[143] Tirzepatide use resulted in clinically meaningful weight reduction among GLP-1 RA naive individuals with obesity or overweight: Results from 2 real-world studies |
Gibble T [1], Chinthammit C [1], Mojdami D [1], Desai K [2], Vallarino C [1], Huang A [3], Dehghan M [1], Bays H [4], Kern S [1] |
[1] Eli Lily and Company; |
|
Tuesday, April 14, 2026 4:30 PM – 5:30 PM CT
12:00 PM – 1:00 PM CT |
Poster Session |
[144] 12-Month |
Gibble T [1], Crocker K [2], Mojdami D [1], Vallarino C [1], Grabner M [2], Upadhyay N [1], Desai K [2], Marrone C [1] |
[1] Eli Lilly and Company; |
|
Tuesday, April 14, 2026 4:30 PM – 5:30 PM CT Wednesday, April 15, 2026 12:00 PM – 1:00 PM CT |
Poster Session |
[104] Real-world effect of ruxolitinib cream: decreased use of additional topical therapies and limited escalation to systemic treatments |
Liu J [1], Desai K [2], Teng C [2] Stockbower G [2], Chen P [2], Willey, V [2], Sturm D [1] |
[1] Incyte Corporation; |
|
Wednesday, April 15, 2026 12:30 PM – 12:50 PM CT |
Spotlight Session |
The Real-World Impact of REMS and Black Box Warnings on Drug Monitoring |
Dudman D [1], Onasanya O [1], Beachler DC [1] |
[1] Carelon Research |
|
Wednesday, April 15, 2026 12:50 PM – 1:10 PM CT |
Spotlight Session |
Impact of Discordant Capecitabine and 5-Fluorouracil Label Warnings on Real-World DPYD Gene Testing |
Onasanya O [1], Dudman D [1], Beachler DC [1] |
[1] Carelon Research |